Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
The USA has recently approved two antimalarial drugs to treat COVID-19. But a new study has found that they may not be effective at fighting off the virus.
Results from a small clinical trial in France, published in the French medical journal, Médecine et Maladies Infectieuses, found that the drugs did not appear to help the immune system clear coronavirus from the body.
The research included 11 patients who were in hospital with COVID-19. Each received the drugs, hydroxychloroquine and azithromycin. After 5-6 days of treatment, the virus was still present in the body. These results are different to a previous study that found the virus had cleared from the body after 5-6 days of treatment with the same drugs.
Both studies had very small numbers of people who were given the drugs and so bigger studies are needed.
An expert working in the field of antiviral research has raised concerns about the drugs. Future President of the International Society for Antiviral Research, Professor Katherine Seley-Radtke, has written an opinion article that urges caution against the use of the drugs before there is enough evidence to show if they are effective.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description